EWMedical devices for structural heart disease
Edwards Lifesciences
- Price
- $101.85
- Discount category
- Far above intrinsic value
- Analysts
- Bullish
- Next earnings
- Feb 4 · · estimated
- Pick status
- Research only
In short
- Thesis
- Investors pay a premium for the leading position of Edwards in TAVR and the fast growth of its mitral and tricuspid therapies, and only several years of fast sales growth with higher margins can earn it.
- Gap
- Slow. Only several years of sales growth near 10% with higher margins can earn the premium.
Company guidance: 2026 sales growth of about 11.5% and adjusted EPS of $2.97 to $3.05; Q4 adjusted EPS of $0.61 to $0.69 (, Q3 2026 earnings release (8-K))
Price history
About
Edwards Lifesciences makes heart valves and devices that repair or replace heart valves. It reports three product groups. Transcatheter aortic valve replacement (TAVR), with the SAPIEN valves, had sales of $1,240 million in Q3 2026. Transcatheter mitral and tricuspid therapies (TMTT), with the PASCAL repair system and the EVOQUE and SAPIEN M3 replacement valves, had sales of $207 million.
Surgical, with valves such as those made of RESILIA tissue, had sales of $264 million. Net sales were $1,715.5 million in Q3 2026 and $6,067.6 million in 2025. Edwards sold its Critical Care product group to BD in September 2024 and a smaller product group in December 2025, so these businesses are discontinued operations. Its shares trade on the New York Stock Exchange.
The head office is in Irvine, California. Bernard Zovighian is Chief Executive Officer.
Thesis
Edwards trades above its intrinsic value because investors pay for its leading position in TAVR and for the fast growth of its mitral and tricuspid therapies. In Q3 2026, sales rose 10.5% to $1.72 billion, TMTT sales rose 44.0% to $207 million, and adjusted EPS rose 19% to $0.80. Edwards now expects 2026 sales growth of about 11.5% and adjusted EPS of $2.97 to $3.05, and it targets average sales growth of about 10% over the longer term.
For the shares to earn this price, three things must be true. TAVR procedures must keep growing as the updated Medicare coverage and data from the EARLY TAVR and PROGRESS trials bring patients to treatment earlier. TMTT must reach its 2026 sales guidance of $780 million to $790 million and keep growing fast.
The adjusted operating margin must rise, after Edwards guided to the high end of 28% to 29% for 2026. The Q4 2026 report and the 2027 guidance, expected in early February 2027, are the next test. Slower TAVR growth or stronger competition can make the premium hard to keep.
Checkpoints
- Nov 4, 2026PassedQ3 2026 results and the 2026 outlookSales growth of 10% or more and a kept or higher EPS outlook pass; a lower outlook fails.Outcome: Sales rose 10.5%, and Edwards raised its 2026 guidance to sales growth of about 11.5% and adjusted EPS of $2.97 to $3.05.
- Feb 4, 2027 · est.PendingQ4 2026 results and 2027 guidance2027 guidance for sales growth near 10% and higher adjusted EPS passes; guidance for slower growth fails.
Recent events
- November 4, 2026Edwards reported Q3 2026 results. Sales rose 10.5% to $1.72 billion, TAVR sales rose 8.0% to $1.24 billion, and TMTT sales rose 44.0% to $207 million. Diluted EPS was $0.53, after an impairment of $220.2 million of an acquired research asset, and adjusted EPS rose 19% to $0.80. Edwards raised its 2026 guidance to sales growth of about 11.5% and adjusted EPS of $2.97 to $3.05. During the quarter, Medicare released its final updated coverage decision for TAVR, and the FDA approved the PASCAL Precision system for tricuspid repair in October.
- July 23, 2026Edwards reported Q2 2026 results. Sales rose 13.6% to $1,741.0 million, and adjusted EPS was $0.78. Diluted EPS was $0.42, which includes a valuation allowance for California research tax credits after a change in state law on June 29, 2026. Edwards raised its 2026 sales growth guidance to 10% to 11% and targeted average sales growth of about 10% over the longer term.
- May 4, 2026Edwards named Theodora (Doretta) Mistras, the Chief Financial Officer of Viatris, as its Chief Financial Officer from the end of May 2026. She follows Scott Ullem.
Show 3 older eventsHide older events
- April 23, 2026Edwards reported Q1 2026 results. Sales rose 16.7% to $1.65 billion, and adjusted EPS was $0.78. Edwards completed a $500 million accelerated share repurchase and raised its 2026 guidance to sales growth of 9% to 11% and adjusted EPS of $2.95 to $3.05.
- February 10, 2026Edwards reported 2025 results. Sales rose 11.5% to $6,067.6 million, and adjusted EPS was $2.56. Diluted EPS from continuing operations was $1.81. Q4 2025 TMTT sales rose more than 40% to $156 million.
- January 9, 2026A U.S. District Court granted the request of the Federal Trade Commission to block the purchase of JenaValve Technology, so Edwards will not buy JenaValve. Edwards raised its 2026 adjusted EPS guidance to $2.90 to $3.05 and continues to develop its own SOJOURN valve for aortic regurgitation.
Latest news and filings
- Last earnings
- November 4, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 4, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed ew-20260930
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KChange of directors or officersFiled ew-20260825
- 10-QQuarterly report for the period ended Jun 30, 2026Filed ew-20260630
- 8-KEarnings releaseFiled Press release and exhibits
- 8-KChange of directors or officers and Shareholder vote resultsFiled ew-20260507
- 10-QQuarterly report for the period ended Mar 31, 2026Filed ew-20260331
- 8-KChange of directors or officers and Investor disclosureFiled ew-20260502
- 8-KEarnings releaseFiled Press release and exhibits
- 10-KAnnual report for the period ended Dec 31, 2025Filed ew-20251231
Risks
Bull case: TMTT sales rose 44.0% to $207 million, and TAVR can reach patients earlier with updated Medicare coverage and data from the EARLY TAVR and PROGRESS trials, so Edwards targets about 10% average sales growth.
- Large medical device companies compete in TAVR and in mitral and tricuspid therapies. New valves or lower prices from competitors can reduce the share and the growth of Edwards.
- Most sales depend on payments from Medicare and other health systems. Lower payments or stricter coverage rules can slow the growth of procedures.
- Edwards is often in patent disputes, and it recorded litigation costs in most quarters of 2025 and 2026. The FTC blocked its purchase of JenaValve in January 2026, so future purchases can also meet antitrust limits.
- A recall or a safety problem with a valve can reduce sales and damage the trust of heart teams in its products.
- Tax changes can raise costs. Edwards expects its 2026 tax rate, without special items, at the high end of 16% to 19%, and a change in California law limits its research tax credits.
Key statistics
- Market cap
- $59B
- Shares of Oct 31, 2026
- P/E (trailing)
- 57.5
- Price of Nov 21, 2026
- EPS (trailing)
- $1.77
- 12 months to Sep 30, 2026
- 52-week range
- $74.66 – $106.80
- To Nov 12, 2026
- Beta
- 0.85
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 3.8M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $4.6B
- Debt
- $600M
- Net cash
- $4.0B
- Credit line
- $750M
- undrawn, to July 2027
Cash against debt
debt covered by cash
When the debt is due
The last debt is due in 2028.
Edwards has net cash. At September 30, 2026, cash and cash equivalents were $3,110.8 million, short-term investments $1,533.9 million and long-term investments $262.6 million. Long-term debt was $598.8 million: the 4.3% senior notes of $600.0 million due June 15, 2028. Edwards had no borrowings under its $750.0 million revolving credit facility, which matures on July 15, 2027. In the first nine months of 2026, net cash provided by operating activities was $1,266.0 million and capital expenditures $195.4 million. Edwards repurchased about $700 million of shares through Q3 2026, and about $1.3 billion of the repurchase authorization was left. There were 575.0 million shares on October 31, 2026. Edwards pays no dividend.
Dividends
Edwards Lifesciences does not pay a dividend.
Source: company filings and market data, read on November 13, 2026.
Questions about Edwards Lifesciences
What does Edwards Lifesciences do?
Edwards Lifesciences makes heart valves and devices that repair or replace heart valves. It reports three product groups. Its market cap is $59B at the current price of $101.85.
When does Edwards Lifesciences report earnings next?
This is an estimate: Edwards Lifesciences may report on February 4, 2027. It last reported results on November 4, 2026.
Is Edwards Lifesciences stock below its intrinsic value?
Edwards Lifesciences stock is far above intrinsic value. This is general information, not advice.
What changed recently at Edwards Lifesciences?
The latest update is from November 4, 2026. Edwards reported Q3 2026 results.
What are the main risks for Edwards Lifesciences?
Large medical device companies compete in TAVR and in mitral and tricuspid therapies. Most sales depend on payments from Medicare and other health systems. Edwards is often in patent disputes, and it recorded litigation costs in most quarters of 2025 and 2026.
How much debt and cash does Edwards Lifesciences have?
At September 30, 2026, Edwards Lifesciences had $600M of debt and $4.6B of cash.
Does Edwards Lifesciences pay a dividend?
No. Edwards Lifesciences does not pay a dividend.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| EWEdwards Lifesciences | 57.5x | n/a | 2.3% | 39.3x |
| BSXBoston Scientific | 17.7x | n/a | 6.0% | 56.1x |
| PODDInsulet | 21.8x | n/a | 4.1% | n/a |
| MDTMedtronic | 24.6x | n/a | 4.2% | 30.1x |
| JNJJohnson & Johnson | 41.1x | n/a | 3.0% | 21.7x |
| Peer median | 23.2x | n/a | 4.2% | n/a |
- EW trades at 57.5x earnings, 148% above the peer median of 23.2x.
- Its free cash flow yield is 2.3%, 1.9 points below the peer median of 4.2%.
- Against its own history, the P/E is 46% above its average of 39.3x over 10 profitable years.
The peers are the companies on this site most like EW. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- BSXBoston ScientificShares: Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- PODDInsuletShares: Regulation and courts
- Intrinsic value
- Well below intrinsic value
- Gap
- Can close
- MDTMedtronicShares: Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
- JNJJohnson & JohnsonShares: Regulation and courts
- Intrinsic value
- Far above intrinsic value
- Gap
- Can close
- ABTAbbott LaboratoriesShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Slow
Loading your notes…
Read it all? Star EW or pass, then go on to the next one.